HANetf ICAV Tech Megatrend Equal Weight UCITS ETF Acc (GBP) (ITEP)
10.80p
(0.96%)
- Add to watchlist
- Create an alert
- This stock can be held in a
10.80p
(0.96%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
10.80p
(0.96%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
1,113.80p
1,119.50p
1,259.60p
London
1,124.20p
1,106.74p
845.10p
$87.62M
11.50p (1.01%) Previous:
11.50p
812
n/a
GBX
ETP Basics
| Issuer: | HANetf ICAV |
|---|---|
| Structure: | ETF |
| Replication method: | Stocks - Optimised |
| Securities lending: | Yes |
| Number of holdings: | 123 |
| Size: | $87.6M |
| Launch date: | 05 October 2018 |
| Launch price: | $7.77 |
| UCITS: | Yes |
| Reporting status: | Yes |
| Domicile: | Ireland |
| Complex product: | Non-complex |
| ISIN: | IE00BDDRF700 |
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Please refer to the FCA website for more information.
Annual & interim reports
Before you invest, please make sure you read the documents below
What is a Value Assessment?
Fund Managers are required to regularly assess whether the fund they manage delivers value to investors. When completing their assessment, they will consider investment performance, service offered, costs and charges, and competitor funds. The Assessment of Value for funds is subject to the Financial Conduct Authority's Collective Investment Scheme (COLL) rules or a Price and Value Assessment (PRIN) for other funds not subject to COLL rules.
Why it matters to investors?
The Value Assessment helps an investor understand how a Fund Manager has considered how their fund has delivered value for money or is expected to deliver value for money. The Fund Manager will explain the actions they are taking if their fund has not delivered value for money or it is not expected to deliver value for money.
Value Assessment
| Value Assessment review date: | 31 January 2025 |
|---|---|
| Value Assessment next review date: | 31 January 2026 |
| Is Assessment of Value required under COLL: | No |
| Outcome of COLL Assessment of Value: | n/a |
| Outcome of PRIN Value Assessment or review: | - |
| Other review related to value and or charges: | - |
| Further information: | - |
Ready to invest?
Important Documents
There are no documents available for this stock.
OBJECTIVE
| Index: | The Solactive Innovative Technologies Index is an Index of Solactive AG and is calculated and distributed by Solactive AG. In particular, the index provides exposure to companies that are involved in innovative and disruptive trends across a broad range of industries.The Index is a Price Return/Net Total Return/Gross Total Return index. For the Price Return Index special cash distributions are reinvested net of cash. The Index is published in US Dollar and adjusted on a semi-annually basis. |
|---|---|
| Aim: |
The Fund seeks to track the price and yield performance, before fees and expenses, of...
Read full aim for HANetf ICAV |
| Leverage: | 100% |
| Currency hedging: | No |
COSTS
| Ongoing Charge (OCF/TER): | 0.59% |
|---|---|
| Management fee: | 0.59% |
| Indicative spread: | 0.25% |
In certain cases, where no TER or OCF is shown, additional costs may apply. Please ensure you have read the Key Investor Information Document, Factsheet, Prospectus and any other relevant documentation prior to investing.
Performance
Not available for this stock.
| Security | Weight |
|---|---|
| TOYOTA INDUSTRIES CORPORATION | 1.22% |
| HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED | 1.19% |
| OSL GROUP LIMITED | 1.17% |
| OKTA | 1.10% |
| TIGA ACQUISITION CORP | 1.06% |
| CAPCOM CO. | 1.05% |
| KONAMI GROUP CORPORATION | 1.04% |
| SUMMIT THERAPEUTICS INC | 1.04% |
| NEXON CO. LTD | 1.04% |
| MEITU | 1.03% |
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.